A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04351243 |
|
Recruitment Status :
Completed
First Posted : April 17, 2020
Results First Posted : December 10, 2021
Last Update Posted : December 14, 2021
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| COVID-19 | Drug: Gimsilumab Drug: Placebo | Phase 2 |
Gimsilumab is a monoclonal antibody against granulocyte macrophage-colony stimulating factor (GM-CSF), which is a myeloid cell growth factor and pro- inflammatory cytokine. Late stages of COVID-19 can be marked by a "cytokine storm" and the overactivation of inflammatory myeloid cells that infiltrate and damage tissue, such as the lungs. Inhibition of GM-CSF may be able to reverse this pathology. The anti-GM-CSF mechanism is distinct from antiviral therapeutic mechanisms and may provide synergistic effects when used in combination.
Study KIN-1901-2001 will consist of a 2-week treatment period (last dose Day 8, if administered) and a 22-week follow-up period, for a total study duration of 24 weeks for each subject. A total of 270 subjects (135 subjects per arm) who have a confirmed diagnosis of COVID-19 with clinical evidence of acute lung injury or ARDS will be entered into the trial.
Subjects will receive a 400 mg dose of gimsilumab on Day 1 and a 200 mg dose of gimsilumab on Day 8, or matching placebo (saline solution) on Day 1 and on Day 8. The Day 8 dose will be omitted if the subject is discharged from the hospital prior to the dose or is no longer in need of supplemental oxygen or ventilatory support for >48 hours.
The primary objective of Study KIN-1901-2001 is to evaluate the impact of IV treatment with gimsilumab on mortality in subjects with lung injury or ARDS secondary to COVID-19.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 227 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Double (Participant, Investigator) |
| Primary Purpose: | Treatment |
| Official Title: | A Multi-Center, Adaptive, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE) |
| Actual Study Start Date : | April 15, 2020 |
| Actual Primary Completion Date : | December 1, 2020 |
| Actual Study Completion Date : | April 1, 2021 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Gimsilumab
Gimsilumab 400 mg on Day 1 Gimsilumab 200 mg on Day 8
|
Drug: Gimsilumab
Gimsilumab is a fully human monoclonal antibody (mAb).
Other Name: KIN-1901 |
|
Placebo Comparator: Placebo
Normal saline on Day 1 Normal saline on Day 8
|
Drug: Placebo
Normal saline |
- Incidence of Mortality [ Time Frame: Day 43 ]"Incidence" is defined as the percent of subjects that died by Day 43
- Proportion of Subjects Who Are Alive and Not on Mechanical Ventilation [ Time Frame: Day 29 ]
- Number of Ventilator-free Days [ Time Frame: Baseline to Day 29 ]Subjects who die will be assigned "0" ventilator-free days
- Time to Hospital Discharge [ Time Frame: Baseline to Day 43 ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Male or non-pregnant female age ≥18 years, inclusive
- Subject (or legally authorized representative) is able and willing to provide written informed consent, which includes compliance with study requirements and restrictions listed in the consent form
- Has laboratory-confirmed SARS-CoV-2 infection as determined by PCR or other approved clinical testing prior to randomization
- Radiographic evidence of bilateral infiltrates
- Subject requires high-flow oxygen or meets clinical classification for ARDS
- Elevated serum CRP or ferritin
- Subjects who have been treated with convalescent plasma (CP) prior to enrollment are eligible if the subject continues to meet all inclusion criteria at screening
- The use of investigational anti-viral treatment (e.g., remdesivir) is allowed if the subject continues to meet all inclusion criteria at screening
Additional inclusion criteria are detailed in the protocol
Exclusion Criteria:
- Evidence of life-threatening dysrhythmia or cardiac arrest on presentation
- Intubated >72 hours
- Absolute neutrophil count < 1,000 per mm3
- Platelet count < 50,000 per mm3
- AST or ALT > 5X upper limit of normal
- eGFR <30 mL/min/1.73m2 or requiring hemofiltration or dialysis
- History of known anti-GM-CSF autoantibodies or pulmonary alveolar proteinosis
- Severe chronic respiratory disease (e.g., COPD, PAH, IPF, ILD) requiring supplemental oxygen therapy or mechanical ventilation pre-hospitalization (e.g., prior to COVID-19 diagnosis)
- Use of any immunomodulatory biologic, cell therapy, or small molecule JAK inhibitor within past 7 days or 5 half lives or planned use of any of these agents unless approved by medical monitor
- Chronic (>4 weeks) use of corticosteroids >10mg/day of prednisone or equivalent
- Known or suspected active and untreated TB, HIV, hepatitis B or C infection
Additional exclusion criteria are detailed in the protocol.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04351243
Show 33 study locations
Documents provided by Kinevant Sciences GmbH:
| Responsible Party: | Kinevant Sciences GmbH |
| ClinicalTrials.gov Identifier: | NCT04351243 |
| Other Study ID Numbers: |
KIN-1901-2001 |
| First Posted: | April 17, 2020 Key Record Dates |
| Results First Posted: | December 10, 2021 |
| Last Update Posted: | December 14, 2021 |
| Last Verified: | December 2021 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Granulocyte macrophage-colony stimulating factor (GM-CSF) Immunomodulator Cytokine storm COVID-19 |
Coronavirus Severe Acute Respiratory Syndrome (SARS) Lung Injury Monoclonal antibody |
|
Gimsilumab COVID-19 Respiratory Distress Syndrome Respiratory Distress Syndrome, Newborn Acute Lung Injury Lung Injury Respiratory Tract Infections Infections Pneumonia, Viral Pneumonia Virus Diseases Coronavirus Infections Coronaviridae Infections |
Nidovirales Infections RNA Virus Infections Lung Diseases Respiratory Tract Diseases Respiration Disorders Infant, Premature, Diseases Infant, Newborn, Diseases Thoracic Injuries Wounds and Injuries Anti-Inflammatory Agents Antiviral Agents Anti-Infective Agents |